BioCatalyst

EWTX — Edgewise Therapeutics, Inc. catalysts

2 verified catalyst event(s) for Edgewise Therapeutics, Inc. (ticker EWTX). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2027-01-01 — A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-01 (month)
in 2mo
ESTIMATED
 READOUT
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Phase 2 · Duchenne Muscular Dystrophy
 EWTX Edgewise Therapeutics, Inc. Sevasemten Dose 1, Sevasemten Dose 2, Se ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dys
Phase 2 · Duchenne Muscular Dystrophy
 EWTX Edgewise Therapeutics, Inc. Sevasemten Dose 1, Sevasemten Dose 2, Se ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.